The Angina (Angina Pectoris) drugs in development market research report provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Angina (Angina Pectoris). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Angina (Angina Pectoris) by 14 companies/universities/institutes. The top development phase for Angina (Angina Pectoris) is phase ii with eight drugs in that stage. The Angina (Angina Pectoris) pipeline has 14 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Angina (Angina Pectoris) pipeline products market are: Hemostemix, Trizell and Arbor Pharmaceuticals.
The key targets in the Angina (Angina Pectoris) pipeline products market include Soluble Guanylate Cyclase (sGC or EC 4.6.1.2), Vascular Endothelial Growth Factor (VEGF) , and Vascular Endothelial Growth Factor D (c Fos Induced Growth Factor or VEGFD or FIGF).
The key mechanisms of action in the Angina (Angina Pectoris) pipeline product include Endothelin 1 Receptor (Endothelin A Receptor or EDNRA) Antagonist with one drug in Phase II. The Angina (Angina Pectoris) pipeline products include four routes of administration with the top ROA being Oral and three key molecule types in the Angina (Angina Pectoris) pipeline products market including Small Molecule, and Gene Therapy.
Angina (Angina Pectoris) overview
Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs with exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood lipid levels, and hypercholesterolemia.
For a complete picture of Angina (Angina Pectoris)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
